Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest radiopharmaceuticals Stories

2013-06-06 12:28:45

BERLIN, BOSTON and MUMBAI, India, June 6, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18(*)) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-12. Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights...

2013-05-27 08:21:23

DALLAS, May 27, 2013 /PRNewswire/ -- The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" analyzes and studies the major market drivers, restraints, and opportunities in Japan, China, India, South Korea, Indonesia, Malaysia, Australia, New Zealand, and Rest of Asia....

2013-05-13 20:22:30

Researchers produce molybdenum-99 from irradiation of low-enriched uranium solution LOS ALAMOS, N.M., May 13, 2013 /PRNewswire-USNewswire/ -- Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium recovery. This demonstrates the viability of the separation process, as well as the potential for environmentally- and...

2013-05-06 11:17:38

Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, an established treatment for cancer patients, could offer a novel therapeutic approach to decrease levels of inflammation in the atherosclerotic plaques of patients with cardiovascular disease (CVD), reported an abstract´ study at the International Conference on Nuclear Cardiology and Cardiac CT, May 5 to 8 in Berlin, Germany. "Our results should act as a stimulus for further exploration of...

2013-05-02 04:21:48

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4(®) bi-functional chelator technology and has extended the collaboration to include...

2013-05-01 16:29:46

CHICAGO, May 1, 2013 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) is pleased to announce the release of the PosiRx® 3000-Series, its latest pharmacy automation systems. The PosiRx® 3000-Series are the first systems to automate and encompass the complete compounding process, from generator elution to dose distribution, of multiple diagnostic SPECT agents in an environment engineered to be ISO Class 5 and USP 797 compliant. Designed for facilities dispensing as many as...

2013-04-25 23:01:39

North American Nuclear Medicine Market / Radiopharmaceutical Therapy Market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. (PRWEB) April 25, 2013 The "North American Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) — Forecast to 2017" analyzes and...

2013-04-23 23:03:25

[292 Pages Report] European Nuclear Medicine/Radiopharmaceuticals Market report segmented the Europe market By Stable Isotopes (Deuterium, C-13), Applications (Cancer/Oncology, Cardiac) [SPECT/PET] & by Geography. (PRWEB) April 23, 2013 The"European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market SPECT/PET Radioisotopes (Technetium, F-18)], Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) — Trends...

2013-04-23 08:32:48

DUBLIN, April 23, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecas" [http://www.researchandmarkets.com/research/kw823x/european_nuclear ] report to their offering. (Logo:...

2013-04-10 23:00:50

RnRMarketResearch.com adds Latest Report on “European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) — Global Trends & Forecast to 2017]” to its store. Dallas, TX (PRWEB) April 10, 2013 The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017...